Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1991 May;46(5):355–359. doi: 10.1136/thx.46.5.355

Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis.

C P van Schayck 1, H Folgering 1, H Harbers 1, K L Maas 1, C van Weel 1
PMCID: PMC463136  PMID: 1829865

Abstract

The bronchodilating responses to 400 micrograms salbutamol and 80 micrograms ipratropium bromide were studied in 188 patients with chronic bronchitis (n = 113) or asthma (n = 75) and mild to moderate airflow obstruction (forced expiratory volume in one second (FEV1) above 50% but below 2 SD of predicted value) in a crossover study on two days a week apart. Both the patients with asthma and the patients with chronic bronchitis varied considerably in their responses to the salbutamol and the ipratropium bromide. The mean increase in FEV1 in the subjects with asthma was higher after salbutamol (0.371 or 18% of the prebronchodilator value) than after ipratropium bromide (0.26 1 or 13%). In chronic bronchitis there was no difference between the increase in FEV1 after salbutamol (0.161 or 7%) and after ipratropium bromide (0.191 or 8%). When patients were categorised into those with a better response to salbutamol 400 micrograms and those with a better response to ipratropium bromide 80 micrograms, patients with chronic bronchitis responded better in general to ipratropium bromide whereas asthmatic patients responded better to salbutamol. The response pattern was also related to allergy and age, allergic patients and patients under 60 being more likely to respond better to salbutamol 400 micrograms than non-allergic patients and older patients, who benefited more from ipratropium bromide 80 micrograms. The response pattern was not related to sex, smoking habits, lung function, bronchial reactivity, respiratory symptoms, or number of exacerbations during the preceding year.

Full text

PDF
355

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boman G., Bäcker U., Larsson S., Melander B., Wåhlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983 Aug;64(6):405–415. [PubMed] [Google Scholar]
  2. Britton J., Hanley S. P., Garrett H. V., Hadfield J. W., Tattersfield A. E. Dose related effects of salbutamol and ipratropium bromide on airway calibre and reactivity in subjects with asthma. Thorax. 1988 Apr;43(4):300–305. doi: 10.1136/thx.43.4.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cockcroft D. W., Killian D. N., Mellon J. J., Hargreave F. E. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy. 1977 May;7(3):235–243. doi: 10.1111/j.1365-2222.1977.tb01448.x. [DOI] [PubMed] [Google Scholar]
  4. Crompton G. K. A comparison of responses to bronchodilator drugs in chronic bronchitis and chronic asthma. Thorax. 1968 Jan;23(1):46–55. doi: 10.1136/thx.23.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Douglas N. J., Davidson I., Sudlow M. F., Flenley D. C. Bronchodilatation and the site of airway resistance in severe chronic bronchitis. Thorax. 1979 Feb;34(1):51–56. doi: 10.1136/thx.34.1.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Easton P. A., Jadue C., Dhingra S., Anthonisen N. R. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med. 1986 Sep 18;315(12):735–739. doi: 10.1056/NEJM198609183151205. [DOI] [PubMed] [Google Scholar]
  7. Fletcher C. M., Pride N. B. Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium. Thorax. 1984 Feb;39(2):81–85. doi: 10.1136/thx.39.2.81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gross N. J., Skorodin M. S. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med. 1984 Aug 16;311(7):421–425. doi: 10.1056/NEJM198408163110701. [DOI] [PubMed] [Google Scholar]
  9. Leitch A. G., Hopkin J. M., Ellis D. A., Merchant S., McHardy G. J. The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis. Thorax. 1978 Dec;33(6):711–713. doi: 10.1136/thx.33.6.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Marini J. J., Lakshminarayan S., Kradjan W. A. Atropine and terbutaline aerosols in chronic bronchitis: efficacy and sites of action. Chest. 1981 Sep;80(3):285–291. doi: 10.1378/chest.80.3.285. [DOI] [PubMed] [Google Scholar]
  11. Petrie G. R., Palmer K. N. Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. Br Med J. 1975 Feb 22;1(5955):430–432. doi: 10.1136/bmj.1.5955.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ruffin R. E., Fitzgerald J. D., Rebuck A. S. A comparison of the bronchodilator activity of Sch 1000 and salbutamol. J Allergy Clin Immunol. 1977 Feb;59(2):136–141. doi: 10.1016/0091-6749(77)90215-9. [DOI] [PubMed] [Google Scholar]
  13. Ruffin R. E., Wolff R. K., Dolovich M. B., Rossman C. M., Fitzgerald J. D., Newhouse M. T. Aerosol therapy with Sch 1000. Short-term mucociliary clearance in normal and bronchitic subjects and toxicology in normal subjects. Chest. 1978 Apr;73(4):501–506. doi: 10.1378/chest.73.4.501. [DOI] [PubMed] [Google Scholar]
  14. Sundt T. M., Jr Was the international randomized trial of extracranial-intracranial arterial bypass representative of the population at risk? N Engl J Med. 1987 Mar 26;316(13):814–816. doi: 10.1056/NEJM198703263161318. [DOI] [PubMed] [Google Scholar]
  15. Ullah M. I., Newman G. B., Saunders K. B. Influence of age on response to ipratropium and salbutamol in asthma. Thorax. 1981 Jul;36(7):523–529. doi: 10.1136/thx.36.7.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. van Schayck C. P., van Weel C., Folgering H., Verbeek A. L., van Herwaarden C. L. Treatment of patients with airflow obstruction by general practitioners and chest physicians. Scand J Prim Health Care. 1989 Oct;7(3):137–142. doi: 10.3109/02813438909087230. [DOI] [PubMed] [Google Scholar]
  17. van der Lende R., Orie N. G. The MRC-ECCS questionnaire on respiratory symptoms (use in epidemiology). Scand J Respir Dis. 1972;53(4):218–226. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES